Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Pharmacokinetic data | |
Metabolism | Renal[1] |
Elimination half-life | ~32 hours[1] |
Excretion | Urine, feces[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C17H15ClN2O |
Molar mass | 298.77 g·mol−1 |
3D model (JSmol) | |
|
Ciclazindol (WY-23409) is an antidepressant and anorectic drug of the tetracyclic chemical class that was developed in the mid to late 1970s, but was never marketed.[2][3] It acts as a norepinephrine reuptake inhibitor, and to a lesser extent as a dopamine reuptake inhibitor.[2][4] Ciclazindol has no effects on the SERT, 5-HT receptors, mACh receptors, or α-adrenergic receptors, and has only weak affinity for the H1 receptor.[4][5][6] As suggested by its local anesthetic properties,[5] ciclazindol may also inhibit sodium channels. It is known to block potassium channels as well.[7][8]
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|
Central |
| ||||||
---|---|---|---|---|---|---|---|
Peripheral | |||||||
|
DAT (DRIs) |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NET (NRIs) |
| ||||||||||||||
SERT (SRIs) |
| ||||||||||||||
VMATs |
| ||||||||||||||
Others |
| ||||||||||||||
Calcium |
| ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Potassium |
| ||||||||||||||||||||||||
Sodium |
| ||||||||||||||||||||||||
Chloride |
| ||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||
Classes | |
---|---|
Antidepressants (TCAs and TeCAs) |
|
Antihistamines |
|
Antipsychotics |
|
Anticonvulsants | |
Others |
|